reason report
bottom line share trade higher today report
result demonstr rel resili overal busi
out-performance pharma consum -- even ex covid
benefit -- offset as-expect covid-driven declin medic
devic think key driver share out-performance today
continu highlight strong posit
balanc sheet cash flow gener perspect dividend
rais basic line histor reiter view
one strongest total return invest vehicl weaken
macroeconom environ defens natur
fact manag provid guidanc
detail framework outlin assumpt covid impact
recoveri seem give investor level comfort time
signific uncertainti even guidanc prove wrong --
like given covid outbreak still evolv --
provid investor start point begin think
beyond world compani pull
guidanc ultim even signific guidanc reduct better
uncertainti stock provid definit guidanc
cfo note assum framework prove correct --
still uncertain point -- hope medic
devic least achiev exceed prior expect
particularli bullish commentari given current environ
importantli underli fundament remain strong
ex-covid includ medic devic saw growth acceler
bp comp-adjust basi regardless covid
compani -- stock -- believ rel resili
amidst macroeconom turmoil ultim could emerg
even stronger posit dust settl given compani
signific financi flexibl continu invest busi
high level
reiter op pt view remain rel
safe volatil market investor compani digest
potenti impact polit uncertainti abroad
solid dividend yield believ continu
deliv averag return sharehold pt
appli price-to-earnings ep
assum stabl price-to-earnings multipl current price-to-earnings
medic suppli devic
ep
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm ep includ stock compens expens
pleas refer page import disclosur price chart analyst certif
estim chang reflect updat guidanc recoveri
larg start sale estim move declin
y/i oper report
vs prior reflect neg fx impact
estim reflect slower recoveri defer
procedur larg start vs prior assumpt
given new assumpt around recoveri timelin sale estim
move lower sale estim move higher
smaller magnitud note current estim impli
procedur loss defer procedur fulli recov
ep estim move lower
larg driven now-low sale estim
rate share outperform price target johnson johnson
histor repres defens stock view johnson johnson also
repres growth acceler stori beyond compani continu
execution-driven turnaround medic devic consum busi offset
pharma patent expir robust growth core drug new launch continu
believ johnson johnson drive sustain organ mid-single-digit top-lin growth
even better high-single-digit bottom-lin growth longer term help strong growth
core new drug stelara tremfya imbruvica darzalex continu
innovation/in-licens re-launch babi brand consum continu
improv medic devic busi ultim return sustain solid
mid-single-digit top-lin growth trajectori potenti above-market growth
dividend yield strong free cash flow gener believ share repres
attract total return vehicl investor
next month believ share trade price target
appli price-to-earnings multipl -- stabl price-to-earnings multipl updat
ep estim -- new ep estim arriv valuat
assum stabl multipl gener rel act defens broader
macroeconom downturn see seem like
continu least time beyond
risk includ failur success integr auri potenti futur acquisit failur
resolv outstand consum consent decre success re-launch product
product recal failur advanc late-stag pipelin success launch
new product protract recoveri procedur volum trend lack real
dollar million except per share data
good sold
research develop expens
pre-tax incom continu oper
revenu
consensu incom statement item includ contributor factset
consensu detail revenu breakdown come first order analyt visibl alpha
consensu
compani report first order analyt consensu visibl alpha consensu svb leerink estim
dollar million except per share data
good sold
research develop expens
pre-tax incom continu oper
revenu
consensu incom statement item includ contributor factset
consensu detail revenu breakdown come first order analyt visibl alpha
consensu
compani report first order analyt consensu visibl alpha consensu svb leerink estim
dollar million except per share data
good sold
research develop expens
pre-tax incom continu oper
net incom attribut non-controlling interest
net incom attribut
sg sale
 sale
oper expens sale
compani report svb leerink estim
 y/i declin report
growth rang
acq /div rang
y/i growth report fx
impact expect oper growth
rang expect adjust
oper growth ex acq /div
rang
y/i growth report fx
impact expect oper growth
rang expect adjust
oper growth ex acq /div
rang
declin report fx
growth rang
acq /div rang
declin report fx
growth rang
acq /div rang
declin report fx
impact expect
oper growth rang
growth ex acq /div rang
report ex fx
report ex fx
report ex fx
report ex fx
report
report
ex olysio ex acquisit
expect expand
margin bp
adjust ep
report reflect declin
ep ex fx
reflect oper declin
 neg fx
impact
adjust ep report
reflect growth ep
oper growth
neg fx impact
adjust ep report
reflect growth ep
oper growth
neg fx impact
adjust ep report
reflect growth ep
oper growth
neg fx impact
adjust ep report
reflect growth ep
oper growth
neg fx impact
adjust ep report
reflect growth ep
oper growth
neg fx impact
adjust ep report
reflect growth ep
oper growth
posit fx impact
adjust ep report
reflect growth ep
oper growth
posit fx impact
adjust ep report
reflect growth ep
oper growth
posit fx impact
adjust ep report
reflect growth ep
oper growth
posit fx impact
expect fx nat impact gross
margin y/i
expect fx impact gross margin
expect fx impact gross margin
expect fx impact gross margin
expect fx impact gross margin
expect complet
remain
share repurchas
expect complet
share repurchas
expect complet
share repurchas
expect complet
share repurchas
